BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc.verified

BTAI

Price:

$2.07

Market Cap:

$77.69M

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials e...[Read more]

Industry

Biotechnology

IPO Date

2018-03-08

Stock Exchange

NASDAQ

Ticker

BTAI

The Enterprise Value as of May 2024 (TTM) for BioXcel Therapeutics, Inc. (BTAI) is 105.88M

According to BioXcel Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 105.88M. This represents a change of -12.96% compared to the average of 121.66M of the last 4 quarters.

BioXcel Therapeutics, Inc. (BTAI) Historical Enterprise Value (quarterly & annually)

How has BTAI Enterprise Value performed in the past?

The mean historical Enterprise Value of BioXcel Therapeutics, Inc. over the last ten years is 284.88M. The current 105.88M Enterprise Value has changed 3.62% with respect to the historical average. Over the past ten years (40 quarters), BTAI's Enterprise Value was at its highest in in the June 2020 quarter at 1.01B. The Enterprise Value was at its lowest in in the March 2017 quarter at 0.

Quarterly (TTM)
Annual

Average

284.88M

Median

189.58M

Minimum

13.68M

Maximum

790.27M

BioXcel Therapeutics, Inc. (BTAI) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of BioXcel Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 1.41%

Maximum Annual Enterprise Value = 790.27M

Minimum Annual Increase = -91.81%

Minimum Annual Enterprise Value = 13.68M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023122.09M-75.69%
2022502.19M64.87%
2021304.59M-61.46%
2020790.27M282.53%
2019206.59M1.41%
201813.68M-91.81%
2017167.04M-3.20%

BioXcel Therapeutics, Inc. (BTAI) Average Enterprise Value

How has BTAI Enterprise Value performed in the past?

The current Enterprise Value of BioXcel Therapeutics, Inc. (BTAI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

309.63M

5-year avg

385.15M

10-year avg

284.88M

BioXcel Therapeutics, Inc. (BTAI) Enterprise Value vs. Peers

How is BTAI’s Enterprise Value compared to its peers?

BioXcel Therapeutics, Inc.’s Enterprise Value is less than Terns Pharmaceuticals, Inc. (316.92M), greater than Amylyx Pharmaceuticals, Inc. (-42407477.00), less than Acumen Pharmaceuticals, Inc. (202.94M), less than Inozyme Pharma, Inc. (310.55M), less than X4 Pharmaceuticals, Inc. (153.70M), less than Day One Biopharmaceuticals, Inc. (1.14B), less than Mirati Therapeutics, Inc. (3.91B), less than Apellis Pharmaceuticals, Inc. (5.12B), less than Exelixis, Inc. (6.03B), less than TG Therapeutics, Inc. (2.58B), less than Viking Therapeutics, Inc. (7.19B), less than Madrigal Pharmaceuticals, Inc. (4.19B), greater than eFFECTOR Therapeutics, Inc. (12.77M), less than Elevation Oncology, Inc. (137.42M), less than Mereo BioPharma Group plc (401.59M), greater than Hepion Pharmaceuticals, Inc. (-7462675.00),

Build a custom stock screener for BioXcel Therapeutics, Inc. (BTAI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioXcel Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BioXcel Therapeutics, Inc. (BTAI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BioXcel Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is BioXcel Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for BioXcel Therapeutics, Inc. (BTAI)?

What is the 3-year average Enterprise Value for BioXcel Therapeutics, Inc. (BTAI)?

What is the 5-year average Enterprise Value for BioXcel Therapeutics, Inc. (BTAI)?

How does the current Enterprise Value for BioXcel Therapeutics, Inc. (BTAI) compare to its historical average?